News

Video

ctDNA as a Marker of Recurrence Risk in stage III CRC: The α-CORRECT Study

Author(s):

Robert E. Schoen, MD, MPH

Dr. Robert E. Schoen presents findings from the α-CORRECT study, highlighting the potential of circulating tumor DNA (ctDNA) as a biomarker for recurrence risk assessment in patients with stage III colorectal cancer.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Video

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Apr 8th 2025 - May 14th 2025

online-activity
View More
Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention
Video

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Apr 7th 2025 - Apr 8th 2026

online-activity
View More
Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas
Video

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas

Apr 3rd 2025 - May 9th 2025

online-activity
View More
Related Content